Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report

doi:10.12998/wjcc.v10.i8.2529

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 8

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3964)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

258

WORD

228

HTML

2063

Figures (1-3)

299

Tables (1-1)

306

Sum=3154

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

252

Download

558

Sum=810

Mar 16, 2022 (publication date) through Nov 19, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Mar 16, 2022; 10(8): 2529-2536
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2529

Full Size Figure Download Figure

Figure 1 Hematoxylin and eosin staining photomicrographs of a right lung tumor tissue biopsy. A: Original magnification (×20); B: Original magnification (×40).

Citation: Liu LF, Deng JY, Lizaso A, Lin J, Sun S. Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report. World J Clin Cases 2022; 10(8): 2529-2536
URL: https://www.wjgnet.com/2307-8960/full/v10/i8/2529.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i8.2529